Mar 26 |
Enveric Biosciences reports Q4 results
|
Mar 26 |
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
|
Mar 19 |
Enveric gains on out-licensing deal of new chemical entities for joint disease treatments
|
Mar 19 |
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
|
Mar 16 |
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
|
Mar 12 |
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
|
Feb 29 |
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
Feb 29 |
Crude Oil Moves Higher; Best Buy Posts Upbeat Earnings
|
Feb 29 |
Nasdaq Gains 100 Points Following PCE Data
|
Feb 29 |
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
|